Trial Profile
Open-label, Single Dose, Tolerability, Pharmacokinetic/Pharmacodynamics and Safety Study of Dabigatran Etexilate Given at the End of Standard Anticoagulant Therapy in Children Aged Less Than 1 Year Old
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Venous thromboembolism
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 26 Feb 2021 Results of population Pharmacokinetic Modeling and Simulation Support from five trials ((NCT02223260, NCT01083732, NCT00844415, NCT01895777, NCT02197416) published in the Journal of Thrombosis and Haemostasis
- 15 Aug 2018 Results published in the Thrombosis and Haemostasis
- 01 Nov 2017 Results published in the Thrombosis and Haemostasis